The estimated lifetime probability of acquiring human papillomavirus in the United States

Sexually Transmitted Diseases

Volumn 41, Issue 11, 2014, Pages 660-664

  Chesson, Harrell W ^a   Dunne, Eileen F ^a   Hariri, Susan ^a   Markowitz, Lauri E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGE; AGED; ARTICLE; FEMALE; HUMAN; INCIDENCE; MALE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROBABILITY; SEXUALITY; UNITED STATES; WART VIRUS; ADOLESCENT; AGE DISTRIBUTION; CHILD; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOGENICITY; PUBLIC HEALTH; RISK FACTOR; THEORETICAL MODEL; VACCINATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROBABILITY; PUBLIC HEALTH; RISK FACTORS; UNITED STATES; VACCINATION;

EID: 84922638992     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000193     Document Type: Article

References (33)

1. Chandra A, Mosher WD, Copen C, et al. Sexual behavior, sexual attraction, and sexual identity in the United States: Data from the 2006-2008 National Survey of Family Growth. Natl Health Stat Rep 2011; 36:1-36.
2. Winer RL, Feng Q, Hughes JP, et al. Risk of female human papil-lomavirus acquisition associated with first male sex partner. J Infect Dis 2008; 197:279-282.
3. Canfell K, Barnabas R, Patnick J, et al. The predicted effect of changes in cervical screening practice in the UK: Results from a modelling study. Br J Cancer 2004; 91:530-536.
4. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151:1158-1171.
5. Rositch AF, Burke AE, Viscidi RP, et al. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: Acquisition and reactivation in older women. Cancer Res 2012; 72:6183-6190.
6. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56:1-24.
7. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218-226.
8. Winer RL, Hughes JP, Feng Q, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011; 20:699-707.
9. Widdice LE, Brown DR, Bernstein DI, et al. Prevalence of human papillomavirus infection in young women receiving the first quadrivalent vaccine dose. Arch Pediatr Adolesc Med 2012; 166: 774-776.
10. Villa LL. Prophylactic HPV vaccines: Reducing the burden of HPV-related diseases. Vaccine 2006; 24(suppl 1):S23-S28.
11. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 1999; 26:S2-S7.
12. Gattoc L, Nair N, Ault K. Human papillomavirus vaccination: Current indications and future directions. Obstet Gynecol Clin North Am 2013; 40:177-197.
13. Delere Y, Schuster M, Vartazarowa E, et al. Cervicovaginal self-sampling is a reliable method for determination of prevalence of human papillomavirus genotypes in women aged 20 to 30 years. J Clin Microbiol 2011; 49:3519-3522.
14. Markowitz LE, Sternberg M, Dunne EF, et al. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009; 200:1059-1067.
15. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181:1911-1919.
16. Baseman JG, Koutsky LA. The epidemiology of human papillo-mavirus infections. J Clin Virol 2005; 32(Suppl 1):S16-S24.
17. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357:1831-1836.
18. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervico-vaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-428.
19. Dunne EF, Datta SD, Markowitz LE. A review of prophylactic human papillomavirus vaccines: Recommendations and monitoring in the US. Cancer 2008; 113:2995-3003.
20. Van de Velde N, Brisson M, Boily MC. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Vaccine 2010; 28:5473-5484.
21. Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis 2011; 204:566-573.
22. Oriel JD. Natural history of genital warts. Br J Vener Dis 1971; 47:1-13.
23. Barnabas RV, Laukkanen P, Koskela P, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3:e138.
24. Garnett GP, Anderson RM. Sexually transmitted diseases and sexual behavior: Insights from mathematical models. J Infect Dis 1996; 174(Suppl 2):S150-S161.
25. Moreira ED Jr, Giuliano AR, Palefsky J, et al. Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men. J Infect Dis 2014; 210:192-199.
26. Dunne EF, Nielson CM, Stone KM, et al. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis 2006; 194:1044-1057.
27. Marrazzo JM. Genital human papillomavirus infection in women who have sex with women: A concern for patients and providers. AIDS Patient Care STDs 2000; 14:447-451.
28. Massad LS, Xie X, Minkoff H, et al. Abnormal pap tests and human papillomavirus infections among HIV-infected and uninfected women who have sex with women. J Low Genit Tract Dis 2014; 18:50-56.
29. Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neo-plasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005; 19:1407-1414.
30. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-related prevalence of anal cancer precursors in homosexual men: The EXPLORE study. J Natl Cancer Inst 2005; 97:896-905.
31. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005; 191:182-192.
32. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillo-mavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208: 385-393.
33. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: National surveillance data. BMJ 2013; 346:f2032.